Abstract: OBJECTIVES: To evaluate the cost-effectiveness of pemigatinib compared to oxaliplatin-L-folinic-acid and fluorouracil plus active symptom control (mFOLFOX+ASC) and ASC alone for the treatment of patients with advanced or metastatic cholangiocarcinoma (CCA)...
Abstract: OBJECTIVES: To evaluate the cost-effectiveness of upadacitinib in patients with active non-radiographic axial spondyloarthritis (nr-axSpA), who have responded inadequately to conventional treatment (NSAIDs), in Greece. METHODS: A cost-effectiveness model,...
Abstract Background and Objective:Ankylosing spondylitis is a chronic, progressive, inflammatory, multidimensional, musculoskeletal disease primarily involving the axial skeleton. In addition, ankylosing spondylitis is associated with increased morbidity and...
Abstract Objectives: To evaluate the cost-effectiveness of lorlatinib compared to 1st generation anaplastic lymphoma kinase (ALK) TKI crizotinib, and 2nd generation TKIs alectinib and brigatinib, for previously untreated patients with ALK+ advanced Non-Small Cell Lung...
Abstract: Purpose: Duchenne Muscular Dystrophy (DMD) is a genetic disorder in boys’ early childhood that adversely affects the cardiac, respiratory, and skeletal muscle’s function and emotional and social functioning as aspects of health-related quality of life...